Travere Therapeutics, Inc.TVTXNASDAQ
Loading
Year-over-year operating cash flow growth rate
| Period | Value |
|---|---|
| Q4 2025 | 323.82% |
| Q3 2025 | 187.32% |
| Q2 2025 | 111.81% |
| Q1 2025 | -18.12% |
| Q4 2024 | 15.97% |
| Q3 2024 | -5.63% |
| Q2 2024 | 66.18% |
| Q1 2024 | -68.87% |
| Q4 2023 | -19.18% |
| Q3 2023 | 14.67% |
| Q2 2023 | 14.57% |
| Q1 2023 | -48.46% |
| Q4 2022 | -38.24% |
| Q3 2022 | -7.39% |
| Q2 2022 | 33.47% |
| Q1 2022 | -105.83% |
| Q4 2021 | -183.83% |
| Q3 2021 | 393.58% |
| Q2 2021 | 124.54% |
| Q1 2021 | -90.87% |
| Q4 2020 | -305.94% |
| Q3 2020 | 204.37% |
| Q2 2020 | 77.87% |
| Q1 2020 | -549.04% |
| Q4 2019 | 68.19% |
| Q3 2019 | 26.10% |
| Q2 2019 | 6.75% |
| Q1 2019 | -474.81% |
| Q4 2018 | 8.57% |
| Q3 2018 | -41.27% |
| Q2 2018 | 81.27% |
| Q1 2018 | -1625.29% |
| Q4 2017 | -115.14% |
| Q3 2017 | 4.54% |
| Q2 2017 | 294.31% |
| Q1 2017 | 58.95% |
| Q4 2016 | -242.56% |
| Q3 2016 | 18.90% |
| Q2 2016 | 211.86% |
| Q1 2016 | -39.94% |